|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
DE69329795T2
(de)
|
1992-10-02 |
2001-07-05 |
Genetics Institute, Inc. |
Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
|
|
ES2332905T3
(es)
|
1993-12-28 |
2010-02-15 |
Allergan, Inc. |
Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
|
|
US5756468A
(en)
|
1994-10-13 |
1998-05-26 |
Wisconsin Alumni Research Foundation |
Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
|
|
US5512547A
(en)
|
1994-10-13 |
1996-04-30 |
Wisconsin Alumni Research Foundation |
Pharmaceutical composition of botulinum neurotoxin and method of preparation
|
|
GB9508204D0
(en)
|
1995-04-21 |
1995-06-07 |
Speywood Lab Ltd |
A novel agent able to modify peripheral afferent function
|
|
US20030095927A1
(en)
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
|
|
AU2340299A
(en)
|
1998-01-26 |
1999-08-09 |
University Of Massachusetts |
Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
|
|
TW574036B
(en)
|
1998-09-11 |
2004-02-01 |
Elan Pharm Inc |
Stable liquid compositions of botulinum toxin
|
|
US6358917B1
(en)
*
|
1999-08-24 |
2002-03-19 |
Jean D. A. Carruthers |
Cosmetic use of botulinum toxin for treatment of downturned mouth
|
|
US6544548B1
(en)
|
1999-09-13 |
2003-04-08 |
Keraplast Technologies, Ltd. |
Keratin-based powders and hydrogel for pharmaceutical applications
|
|
US6844324B1
(en)
|
1999-11-12 |
2005-01-18 |
Massachusetts Institute Of Technology |
Modular peptide mediated intracellular delivery system and uses therefore
|
|
IL149778A0
(en)
|
1999-11-22 |
2002-11-10 |
Universal Preservation Technologies Inc |
Preservation of sensitive biological material
|
|
US20030118598A1
(en)
*
|
2000-02-08 |
2003-06-26 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
|
ATE519494T1
(de)
|
2000-02-08 |
2011-08-15 |
Allergan Inc |
Pharmazeutische zusammensetzungen mit botulinum- toxin
|
|
US7780967B2
(en)
*
|
2000-02-08 |
2010-08-24 |
Allergan, Inc. |
Reduced toxicity Clostridial toxin pharmaceutical compositions
|
|
US6670322B2
(en)
|
2000-06-01 |
2003-12-30 |
Wisconsin Alumni Research Foundation |
Method of targeting pharmaceuticals to motor neurons
|
|
US20040033241A1
(en)
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
|
EP1301213B1
(en)
*
|
2000-07-21 |
2017-01-18 |
ReVance Therapeutics, Inc. |
Multi-component biological transport systems
|
|
US20040220100A1
(en)
|
2000-07-21 |
2004-11-04 |
Essentia Biosystems, Inc. |
Multi-component biological transport systems
|
|
US7255865B2
(en)
*
|
2000-12-05 |
2007-08-14 |
Allergan, Inc. |
Methods of administering botulinum toxin
|
|
US6787517B1
(en)
*
|
2000-12-29 |
2004-09-07 |
Allergan, Inc. |
Agent and methods for treating pain
|
|
US20020197278A1
(en)
|
2001-06-21 |
2002-12-26 |
Surromed, Inc. |
Covalent coupling of botulinum toxin with polyethylene glycol
|
|
AU2003211990A1
(en)
*
|
2002-02-14 |
2003-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
|
WO2003101483A1
(en)
|
2002-05-31 |
2003-12-11 |
Solux Corporation |
Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
|
|
US20040009180A1
(en)
|
2002-07-11 |
2004-01-15 |
Allergan, Inc. |
Transdermal botulinum toxin compositions
|
|
US8119109B2
(en)
*
|
2002-10-25 |
2012-02-21 |
Foamix Ltd. |
Foamable compositions, kits and methods for hyperhidrosis
|
|
US9265725B2
(en)
*
|
2002-10-25 |
2016-02-23 |
Foamix Pharmaceuticals Ltd. |
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
|
|
RU2206337C1
(ru)
|
2002-10-29 |
2003-06-20 |
Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" |
Лекарственный препарат для лечения мышечных дистоний и способ его получения
|
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
|
DE10333317A1
(de)
|
2003-07-22 |
2005-02-17 |
Biotecon Therapeutics Gmbh |
Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
|
|
US20100266638A1
(en)
*
|
2004-02-26 |
2010-10-21 |
Allergan, Inc. |
Headache treatment method
|
|
CN1946431B
(zh)
*
|
2004-03-03 |
2011-12-07 |
雷文斯治疗公司 |
用于肉毒毒素的局部施用和透皮递送的组合物和方法
|
|
CA2558676C
(en)
*
|
2004-03-03 |
2019-04-16 |
Essentia Biosystems, Inc. |
Compositions and methods for topical diagnostic and therapeutic transport
|
|
US9211248B2
(en)
*
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
GB2416122A
(en)
*
|
2004-07-12 |
2006-01-18 |
Ipsen Ltd |
Botulinum neurotoxin composition
|
|
BRPI0513850A
(pt)
*
|
2004-07-26 |
2008-05-20 |
Merz Pharma Gmbh & Co Kgaa |
composição terapêutica com uma neurotoxina botulìnica
|
|
US20070196364A1
(en)
*
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
|
GB2419526A
(en)
|
2004-10-28 |
2006-05-03 |
Ipsen Ltd |
Pharmaceutical composition containing botulinum neurotoxin
|
|
PL1776137T3
(pl)
|
2004-08-04 |
2015-03-31 |
Ipsen Biopharm Ltd |
Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
|
|
ES2526913T3
(es)
|
2004-08-04 |
2015-01-16 |
Ipsen Biopharm Limited |
Composición farmacéutica que contiene neurotoxina 2 botulínica
|
|
US9314431B2
(en)
*
|
2005-02-14 |
2016-04-19 |
Transdermal Corp |
Solubilized benzoyl small molecule
|
|
US7838011B2
(en)
*
|
2005-02-14 |
2010-11-23 |
Pankaj Modi |
Stabilized protein compositions for topical administration and methods of making same
|
|
US7727537B2
(en)
*
|
2005-02-14 |
2010-06-01 |
Dpm Therapeutics Corp. |
Stabilized compositions for topical administration and methods of making same
|
|
SG160357A1
(en)
*
|
2005-03-03 |
2010-04-29 |
Revance Therapeutics Inc |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
US8323666B2
(en)
*
|
2005-08-01 |
2012-12-04 |
Allergan, Inc. |
Botulinum toxin compositions
|
|
US8168206B1
(en)
*
|
2005-10-06 |
2012-05-01 |
Allergan, Inc. |
Animal protein-free pharmaceutical compositions
|
|
US8137677B2
(en)
*
|
2005-10-06 |
2012-03-20 |
Allergan, Inc. |
Non-protein stabilized clostridial toxin pharmaceutical compositions
|
|
NZ568216A
(en)
*
|
2005-11-17 |
2012-09-28 |
Revance Therapeutics Inc |
Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
|
|
US9486408B2
(en)
*
|
2005-12-01 |
2016-11-08 |
University Of Massachusetts Lowell |
Botulinum nanoemulsions
|
|
US7899450B2
(en)
*
|
2006-03-01 |
2011-03-01 |
Telecommunication Systems, Inc. |
Cellular augmented radar/laser detection using local mobile network within cellular network
|
|
US20090123527A1
(en)
*
|
2006-07-24 |
2009-05-14 |
Akorn, Inc. |
Method of inducing topical anesthesia and transdermal patch
|
|
US20080226729A1
(en)
*
|
2006-09-08 |
2008-09-18 |
Becton, Dickinson And Company |
Stable powder formulations of alum-adsorbed vaccines
|
|
WO2008070538A2
(en)
*
|
2006-12-01 |
2008-06-12 |
Anterios, Inc. |
Micellar nanoparticles comprising botulinum toxin
|
|
AU2007234612B2
(en)
*
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
FR2910327B1
(fr)
*
|
2006-12-22 |
2013-04-26 |
Scras |
Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
|
|
JP2010514781A
(ja)
*
|
2006-12-29 |
2010-05-06 |
ルバンス セラピュティックス インク． |
Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
|
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
|
CA2686642A1
(en)
|
2007-06-01 |
2008-12-04 |
Merz Pharma Gmbh & Co. Kgaa |
Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
|
|
US8617568B2
(en)
*
|
2007-07-10 |
2013-12-31 |
Medy-Tox, Inc. |
Pharmaceutical liquid composition of botulinum toxin with improved stability
|
|
CN101842107B
(zh)
|
2007-07-26 |
2014-04-23 |
雷文斯治疗公司 |
抗微生物肽，组合物和使用方法
|
|
WO2009056651A1
(en)
*
|
2007-11-02 |
2009-05-07 |
Cytos Biotechnology Ag |
Angiotensin-carrier formulation
|
|
US9107815B2
(en)
*
|
2008-02-22 |
2015-08-18 |
Allergan, Inc. |
Sustained release poloxamer containing pharmaceutical compositions
|
|
KR20110106346A
(ko)
*
|
2008-12-10 |
2011-09-28 |
알러간, 인코포레이티드 |
클로스트리디움 독소 약제학적 조성물
|
|
AU2009332947C1
(en)
*
|
2008-12-31 |
2019-01-03 |
Revance Therapeutics, Inc. |
Injectable botulinum toxin formulations
|
|
EP2248518B1
(en)
*
|
2009-04-17 |
2013-01-16 |
Merz Pharma GmbH & Co. KGaA |
Formulation for stabilizing proteins, peptides or mixtures thereof.
|
|
EP2445521A4
(en)
*
|
2009-06-25 |
2015-08-26 |
Revance Therapeutics Inc |
ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
|
|
AU2010270722B2
(en)
*
|
2009-07-06 |
2015-06-04 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
WO2011028962A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody coformulations
|
|
PH12012500549A1
(en)
*
|
2009-10-21 |
2017-08-23 |
Revance Therapeutics Inc |
Methods and systems for purifying non-complexed botulinum neurotoxin
|
|
AU2010312289B2
(en)
*
|
2009-10-30 |
2015-04-23 |
Duoject Medical Systems Inc. |
Inter vial transfer system
|
|
SG181420A1
(en)
*
|
2009-10-30 |
2012-07-30 |
Revance Therapeutics Inc |
Device and method for topical application of therapeutics or cosmetic compositions
|
|
JP5990176B2
(ja)
*
|
2010-10-12 |
2016-09-07 |
メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン |
タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
|
|
PT2661276T
(pt)
*
|
2011-01-07 |
2017-10-06 |
Revance Therapeutics Inc |
Composição tópica que inclui uma tóxina botulínica e um corante
|
|
WO2012134240A2
(ko)
*
|
2011-03-31 |
2012-10-04 |
(주)메디톡스 |
보툴리눔 독소의 동결건조제제
|
|
US20130224268A1
(en)
*
|
2012-02-27 |
2013-08-29 |
Newgen Biopharma Corp. |
Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
|
|
CA2889833A1
(en)
*
|
2012-10-28 |
2014-05-01 |
Revance Therapeutics, Inc. |
Compositions and methods for safe treatment of rhinitis
|
|
GB201407525D0
(en)
*
|
2014-04-29 |
2014-06-11 |
Syntaxin Ltd |
Manufacture of recombinant clostridium botulinum neurotoxins
|
|
CN107106780B
(zh)
|
2014-12-23 |
2020-10-16 |
莫茨制药有限及两合公司 |
肉毒杆菌毒素预填充式容器
|
|
AU2016343748A1
(en)
*
|
2015-10-29 |
2018-05-17 |
Revance Therapeutics, Inc. |
Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
|
|
FI126979B
(en)
*
|
2016-02-29 |
2017-09-15 |
Faron Pharmaceuticals Oy |
Lyophilized pharmaceutical formulation and its use
|
|
AU2017250267A1
(en)
*
|
2016-04-12 |
2018-11-08 |
Illustris Pharmaceuticals, Inc. |
Compositions for topical application of compounds
|
|
HUE052023T2
(hu)
|
2016-05-27 |
2021-04-28 |
Ipsen Biopharm Ltd |
Triptofánnal vagy tirozinnal stabilizált folyékony neurotoxin készítmény
|
|
EP3675900A4
(en)
*
|
2017-08-28 |
2021-05-05 |
Revance Therapeutics, Inc. |
Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
|
|
EP3703738A4
(en)
*
|
2017-11-03 |
2021-09-08 |
ReVance Therapeutics, Inc. |
BOTULINIC TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTARY FASCIITIS, WITH EXTENDED DURATION OF EFFECT
|
|
SG11202005239YA
(en)
*
|
2017-12-04 |
2020-07-29 |
Revance Therapeutics Inc |
Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
|